Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for VRTX
+1.50 (1.78%)
Real-time:   10:51AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 83.62 - 86.10
52 week 75.90 - 143.45
Open 83.70
Vol / Avg. 144,825.00/2.05M
Mkt cap 21.18B
P/E     -
Div/yield     -
EPS -1.65
Shares 247.35M
Beta 0.53
Inst. own 97%
Jul 27, 2016
Q2 2016 Vertex Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2016
Vertex Pharmaceuticals Inc Annual Shareholders Meeting - 9:30AM EDT - Add to calendar
Jun 3, 2016
Vertex Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:30AM EDT - Add to calendar
Apr 27, 2016
Q1 2016 Vertex Pharmaceuticals Inc Earnings Call
Apr 27, 2016
Q1 2016 Vertex Pharmaceuticals Inc Earnings Release
Mar 15, 2016
Vertex Pharmaceuticals Inc at Barclays Global Healthcare Conference
Mar 8, 2016
Vertex Pharmaceuticals Inc at Cowen Health Care Conference
Mar 1, 2016
Vertex Pharmaceuticals Inc at Credit Suisse One-on-One Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -9.07% -56.98%
Operating margin -3.60% -45.23%
EBITD margin - -38.97%
Return on average assets -5.81% -24.34%
Return on average equity -17.60% -55.22%
Employees 1,950 -
CDP Score - -


50 Northern Ave
BOSTON, MA 02210-1862
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. Its marketed medicines are ORKAMBI and KALYDECO, which are approved to treat patients with CF having specific mutations in their CF transmembrane conductance regulator (CFTR) gene. It has multiple development programs in the field of CF, including VX-661, VX-371, and VX-152 and VX-440. It is engaged in various other research and mid- and early-stage development programs, such as programs in the areas of oncology, pain and neurology. Its oncology drug candidates include VX-970, VX-803 and VX-984; pain drug candidates include VX-150 and VX-241, and acute spinal cord injury drug candidate include VX-210.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
David Altshuler M.D., Ph.D. Executive Vice President - Global Research, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Michael J. Parini J.D. Executive Vice President and Chief Legal Officer
Age: 41
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Executive Vice President - Global Government Strategy, Market Access and Value
Age: 48
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 49
Bio & Compensation  - Reuters
Elaine S. Ullian Co-Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Sangeeta M. Bhatia M.D, Ph.D Director
Age: 47
Bio & Compensation  - Reuters